Suda Ltd (SUD)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Suda Ltd (SUD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013311
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Suda Ltd (Suda) is a drug delivery company that offers oro-mucosal administration solutions. The company’s products include artimist, zolpimist, SUD-001, SUD-002, SUD-003, SUD-004 and SUD-005. Its artimist is a sub-lingual spray for the treatment of p. falciparum severe paediatric malaria. Suda’s SUD-001 is an oral spray formulation of sumatriptan for the treatment of acute migraine in adults. The company’s SUD-003 is an oral spray formulation of sildenafil for the treatment of erectile dysfunction. It uses OroMist, oro-mucosal drug delivery technology to develop pharmaceutical products. The company offers its products in forms of tablets and capsules. It caters to hospitals, aged care facilities, pharmacies, mining companies and other healthcare providers. Suda is headquartered in Perth, Western Australia, Australia.

Suda Ltd (SUD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Suda Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Suda Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Suda Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Suda Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Suda Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Suda Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Suda Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Suda to Acquire Anagrelide from Aluztra Bio 11
Suda Completes Acquisition Of NovaMist Technology And Product Pipeline From Suda 12
Suda Completes Acquisition Of NovaMist Technology From NovaDel Pharma For US$0.4 Million 14
Licensing Agreements 16
Eddingpharm Enters into Licensing Agreement with Suda 16
Equity Offering 17
Suda Raises USD1.1 Million in Private Placement of Shares 17
Suda Completes Private Placement Of Shares For US$5.2 Million 19
Suda Completes Seventh Tranche Of Private Placement Of Shares For US$0.1 Million 20
Eastland Medical Systems Completes Rights Issue Of US$3.6 Million 22
Eastland Medical Systems Completes Private Placement Of Shares For US$0.8 Million 23
Debt Offering 24
Suda to Raise USD0.6 Million in Public Offering of 8% Convertible Notes Due March 2019 24
Suda Announces Private Placement Of Convertible Security For US$0.6 Million 25
Acquisition 26
Suda Acquires 20% Stake in Malaria Research Company from Proto Pharma and London Pharma for USD0.8 Million 26
Suda Ltd – Key Competitors 27
Suda Ltd – Key Employees 28
Suda Ltd – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Jul 24, 2017: Suda Announces Strong FY2017 Revenue Growth For Westcoast Subsidiary 30
Feb 27, 2017: Suda announces strong revenue growth for westcoast subsidiary 31
Oct 31, 2016: Suda: Appendix 4C For First Quarter Fy 2017 32
Aug 31, 2016: Suda: Results for announcement to the market 33
Legal and Regulatory 34
Jul 31, 2017: Suda Achieves Iso 9001:2015 Accreditation 34
Jun 03, 2016: Suda Announces Update on HC Berlin Pharma 35
Other Significant Developments 36
Oct 31, 2017: Suda: Appendix 4C For First Quarter FY2018 36
Jul 27, 2017: SUDA: Appendix 4C For Fourth Quarter FY2017 37
Feb 20, 2017: SUDA: Company Update Regarding Suspension 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Suda Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Suda Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Suda Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Suda Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Suda Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Suda Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Suda Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Suda to Acquire Anagrelide from Aluztra Bio 11
Suda Completes Acquisition Of NovaMist Technology And Product Pipeline From Suda 12
Suda Completes Acquisition Of NovaMist Technology From NovaDel Pharma For US$0.4 Million 14
Eddingpharm Enters into Licensing Agreement with Suda 16
Suda Raises USD1.1 Million in Private Placement of Shares 17
Suda Completes Private Placement Of Shares For US$5.2 Million 19
Suda Completes Seventh Tranche Of Private Placement Of Shares For US$0.1 Million 20
Eastland Medical Systems Completes Rights Issue Of US$3.6 Million 22
Eastland Medical Systems Completes Private Placement Of Shares For US$0.8 Million 23
Suda to Raise USD0.6 Million in Public Offering of 8% Convertible Notes Due March 2019 24
Suda Announces Private Placement Of Convertible Security For US$0.6 Million 25
Suda Acquires 20% Stake in Malaria Research Company from Proto Pharma and London Pharma for USD0.8 Million 26
Suda Ltd, Key Competitors 27
Suda Ltd, Key Employees 28
Suda Ltd, Subsidiaries 29

★海外企業調査レポート[Suda Ltd (SUD)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cleveland BioLabs Inc (CBLI):企業の財務・戦略的SWOT分析
    Summary Cleveland BioLabs Inc (Cleveland) is a bio pharmaceutical company that develops and commercializes drugs to treat cancer, orphan indications and protect healthy tissues from radiation and chemotherapy. The company’s product includes entolimod, a recombinant protein that acts as an agonist of …
  • Haisco Pharmaceutical Group Co Ltd (002653):製薬・医療:M&Aディール及び事業提携情報
    Summary Haisco Pharmaceutical Group Co Ltd (Haisco Pharma), formerly Xizang Haisco Pharmaceutical Group Co Ltd is a developer and marketer of chemical drug preparations. The company offers parenteral nutrition drugs, first-aid drugs, antibiotics, anesthetic agents, nervous system drugs, digestive sy …
  • West African Development Bank:電力:M&Aディール及び事業提携情報
    Summary West African Development Bank (BOAD) is a public financial institution focused on the balanced development of its member countries of the West African Monetary Union (WAMU). The institution offers financial advisory services; guarantees of bond loans; financial assistance in project preparat …
  • Deutsche Bahn AG:企業の戦略・SWOT・財務情報
    Deutsche Bahn AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Bahn AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Teva Pharmaceutical Industries Limited:企業の戦略・SWOT・財務情報
    Teva Pharmaceutical Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Teva Pharmaceutical Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Cancer Research Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Cancer Research Institute (CRI) is a non-profit cancer research organization that discovers and develops immunotherapy for treating various types of cancer. The organization offers clinical trials for breast cancer, colorectal cancer, lung cancer, melanoma and prostate cancer. Its programs c …
  • MorphoSys AG (MOR)-製薬・医療分野:企業M&A・提携分析
    Summary MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product include MOR208, MOR202, MOR103, MOR209/ES414, MOR106, and MOR107, among others. It drugs are used in the treatment of different types of canc …
  • Martin Midstream Partners LP (MMLP):企業の財務・戦略的SWOT分析
    Martin Midstream Partners LP (MMLP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Nila Infrastructures Ltd:企業の戦略・SWOT・財務分析
    Nila Infrastructures Ltd - Strategy, SWOT and Corporate Finance Report Summary Nila Infrastructures Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Aflac Incorporated:企業の戦略・SWOT・財務情報
    Aflac Incorporated - Strategy, SWOT and Corporate Finance Report Summary Aflac Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Enstar Group Ltd.:企業のM&A・事業提携・投資動向
    Enstar Group Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Enstar Group Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Ichor Medical Systems Inc-製薬・医療分野:企業M&A・提携分析
    Summary Ichor Medical Systems Inc (Ichor) is a medical equipment company that commercializes electroporation technology for the delivery of vaccines and DNA drugs. The company electroporation technology is used for the treatment and prevention of debilitating diseases. Its trigrid provides DNA drugs …
  • Cardiovascular Systems Inc (CSII):企業の財務・戦略的SWOT分析
    Summary Cardiovascular Systems Inc (CSI) is a medical device company that develops and commercializes products for the treatment of peripheral and coronary vascular disease. The company's products include peripheral orbital atherectomy system, coronary orbital atherectomy system, crowns, and accesso …
  • ReWalk Robotics Ltd (RWLK):企業の財務・戦略的SWOT分析
    Summary ReWalk Robotics Ltd (ReWalk) is a medical device company that designs, develops and commercializes exoskeletons. The company offers walk restoration devices for people with lower limb disabilities to stand and walk once again. Its products include ReWalk personal system and ReWalk rehabilita …
  • Al Kamil Power Company SAOG (KPCS):企業の財務・戦略的SWOT分析
    Al Kamil Power Company SAOG (KPCS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Shinva Medical Instrument Co Ltd (600587):医療機器:M&Aディール及び事業提携情報
    Summary Shinva Medical Instrument Co., Ltd. (Shinva Medical) manufactures and markets medical instruments and environmental protection equipment for various healthcare markets. The company’s product portfolio includes sterilizers, radiotherapy equipment, digital diagnosis equipment, surgical instrum …
  • Univision Communications Inc.:企業の戦略・SWOT・財務分析
    Univision Communications Inc. - Strategy, SWOT and Corporate Finance Report Summary Univision Communications Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Aurora National Life Assurance Company:企業の戦略・SWOT・財務情報
    Aurora National Life Assurance Company - Strategy, SWOT and Corporate Finance Report Summary Aurora National Life Assurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Henry Schein Inc (HSIC):企業の財務・戦略的SWOT分析
    Henry Schein Inc (HSIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Evofem Inc-医療機器分野:企業M&A・提携分析
    Summary Evofem Inc (Evofem) is a healthcare solution provider that discovers, develops and commercializes prescription and consumer products. The company’s product pipeline includes amphora and nestorone. Evofem improves reproductive health and wellness options for women. It develops products for co …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆